ReviewInfectious diseases and therapy2021
Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis.
Review in Infectious diseases and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- The value of fecal calprotectin inFrontiers in physiology · 2022Pooled it
- Clostridioides difficile Near-Patient Testing Versus Centralized Testing: A Pragmatic Cluster Randomized Crossover Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Lab-in-a-Tube System Integrating Hierarchically Wrinkled Electrodes and DNAzyme-Functionalized Beads for Diagnosis of Clostridioides difficile Infection.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Biofilm Formation and Para-cresol Production by Clostridioides difficile Under the Influence of Phytonutrients from Rhus chinensis.Current microbiology · 2026Article
- Molecular epidemiology ofMicrobiology spectrum · 2026Article
- Development and Evaluation of Exosporium-Anchored Bioluminescent and Fluorescent Reporters for TrackingACS synthetic biology · 2026Article
- A longitudinal analysis of Clostridioides difficile virulence profiles across three geographic regions in Israel (2020-2022).Annals of clinical microbiology and antimicrobials · 2026Article
- Clinical outcomes of toxin-positive versus toxin-negative/NAAT-positive Clostridioides difficile infection in South Korea: a single-center retrospective cohort study.BMC infectious diseases · 2026Article
- Article
- Practice Variations in the Management ofGastro hep advances · 2026Article
- Challenges and Strategies in Managing RecurrentGeriatrics (Basel, Switzerland) · 2025Article
- Peptidoglycan LD-Transpeptidases.Antibiotics (Basel, Switzerland) · 2025Review
- Global burden and trends of theAnnals of medicine · 2025Observational
- Subacute Diarrhea: A Rare Presentation of Anaplastic T-Cell Lymphoma.Clinical case reports · 2025Article
- Lipidomics, Microbiota, and IntestinalInternational journal of molecular sciences · 2025Review
- Risk factors and outcomes of Clostridioides difficile infection in patients with colorectal cancer: critical perspective in management.Gut pathogens · 2025Review
- Bioengineered Probiotics for Clostridioides difficile Infection: An Overview of the Challenges and Potential for This New Treatment Approach.Probiotics and antimicrobial proteins · 2025Review
- Comprehensive review ofWorld journal of gastrointestinal pharmacology and therapeutics · 2025Article
- Predicting positiveHeliyon · 2025Article
- Factors for Treatment Failure After Fecal Microbiota Transplantation inMicroorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile infection (CDI) is a leading cause of healthcare-associated infections, accounting for significant disease burden and mortality. The clinical spectrum of C. difficile ranges from asymptomatic colonization to toxic megacolon and fulminant colitis. CDI is characterized by new onset of ≥ 3 unformed stools in 24 h and is confirmed by laboratory test for the presence of toxigenic C. difficile. Currently, laboratory tests to diagnose CDI include toxigenic culture, glutamate dehydrogenase (GDH), nucleic acid amplification test (NAAT), and toxins A/B enzyme immunoassay (EIA). The sensitivities of these tests are variable with toxin EIA ranging from 53 to 60% and with NAAT at about 95%. Overall, the specificity is > 90% for these methods. However, the positive predictive value (PPV) depends on the disease prevalence with lower CDI rates associated with lower PPVs.Notably, the widespread use of the highly sensitive NAAT and its relatively lower clinical specificity have led to overdiagnosis of C. difficile by identifying carriers when NAAT is used as the sole diagnostic method. Overdiagnosis of C. difficile has resulted in unwarranted treatment, possibly attributing to resistance to metronidazole and vancomycin, increased risk for overgrowth of vancomycin-resistant enterococci strains in stool specimens, and increased hospitalization thereby impacting patient safety and healthcare costs.Strategies to optimize the clinical sensitivity and specificity of current laboratory tests are critical to differentiate the clinical CDI from colonization. To achieve high diagnostic yield, if preagreed institutional criteria for stool submission are not used, a multistep approach to CDI diagnosis is recommended, such as either GDH or NAAT followed by toxins A/B EIA in conjunction with laboratory stewardship by evaluating C. difficile test orders for appropriateness and providing feedback. Furthermore, antimicrobial stewardship, along with provider education on appropriate testing for C. difficile, is vital to differentiate CDI from colonization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.